Table 1 FA-PNEU results and antibiotic management (this table should appear after the result section)
From: Co-infections in COVID-19 critically ill and antibiotic management: a prospective cohort analysis
Patient no. | Sample type | FA-PNEU results | Treatment switch initiated by FA-PNEU results | |
|---|---|---|---|---|
Detected pathogens (106 ≥ 107) | Initial antibiotherapy | Subsequent antibiotherapy | ||
1 | Sputum | – | None | None |
2 | ETA | Pseudomonas aeruginosa | None | Ceftazidime |
3 | ETA | Moraxella catarrhalis | None | Cefuroxime |
4 | ETA | – | None | None |
5 | ETA | – | None | None |
6 | Sputum | – | None | None |
7 | ETA | – | None | None |
8 | ETA | – | Cefuroxime | None |
9 | Sputum | Haemophilus influenza | None | Cefuroxime |
10 | ETA | – | None | None |
11 | ETA | – | Cefuroxime | None |
12 | ETA | M. catarrhalis | Cefuroxime | Cefuroxime |
13 | ETA | Staphylococcus aureus | None | Flucloxacilline |
14 | ETA | – | None | None |
15 | ETA | – | None | None |
16 | ETA | Streptococcus agalactiae | Cefuroxime | Cefuroxime |
17 | Sputum | – | None | None |
18 | ETA | S. aureus | None | Flucloxacilline |
19 | ETA | – | Cefuroxime | None |
20 | ETA | – | None | None |
21 | ETA | S. aureus | Amoxicilline - clavulanic acid | Amoxicilline - clavulanic acid |
22 | Sputum | H. influenza | None | Cefuroxime |
23 | ETA | H. influenza | None | Cefuroxime |
24 | ETA | – | Cefuroxime | None |
25 | ETA | S. aureus | Cefuroxime | Flucloxacilline |
26 | ETA | – | None | None |
27 | Sputum | S. aureus + mecA/C | None | Vancomycine |
28 | Sputum | – | None | None |
29 | Sputum | – | None | None |
30 | Sputum | – | Piperacilline-tazobactam | None |
31 | ETA | – | None | None |
32 | ETA | S. aureus + mecA/C − H. influenza | None | Vancomycine + cefuroxime |